PureTech Health (LSE:PRTC) Cash And Cash Equivalents : £221.99 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is PureTech Health Cash And Cash Equivalents?

PureTech Health's quarterly cash and cash equivalents increased from Dec. 2023 (£150.95 Mil) to Jun. 2024 (£242.46 Mil) but then stayed the same from Jun. 2024 (£242.46 Mil) to Dec. 2024 (£221.99 Mil).

PureTech Health's annual cash and cash equivalents increased from Dec. 2022 (£123.04 Mil) to Dec. 2023 (£150.95 Mil) and increased from Dec. 2023 (£150.95 Mil) to Dec. 2024 (£221.99 Mil).

PureTech Health Cash And Cash Equivalents Historical Data

The historical data trend for PureTech Health's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health Cash And Cash Equivalents Chart

PureTech Health Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

300.49

350.21

123.04

150.95

221.99

PureTech Health Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															123.04	277.61	150.95	242.46	221.99

PureTech Health Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

PureTech Health (LSE:PRTC) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

PureTech Health Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of PureTech Health's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

PureTech Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (LSE:PRTC) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

PRTC:USA PTCHF:USA PRTCl:UK 0VQ:Germany

Address

6 Tide Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.puretechhealth.com

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.